on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies Files 2026 Half-Year Report with AMF
DBV Technologies, a late-stage biopharmaceutical company listed on Euronext and Nasdaq, has filed its 2026 Half-Year Report with the French market authority, Autorité des Marchés Financiers (AMF). The report, covering the semester ending June 30, 2026, is available in French and can be accessed on the company's website and the AMF website.
The document provides an overview of DBV Technologies' advancements, including developments in their proprietary VIASKIN® patch technology aimed at treating food allergies. This innovative treatment employs epicutaneous immunotherapy (EPIT) to potentially desensitize the immune system to allergens. The company continues to conduct clinical trials, particularly focusing on peanut allergies in young children.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news